Midatech Pharma PLC (LON:MTPH) had its target price cut by analysts at N+1 Singer from GBX 140 ($1.84) to GBX 96 ($1.26) in a report released on Friday. The firm currently has a “buy” rating on the stock. N+1 Singer’s target price points to a potential upside of 90.10% from the company’s current price.

Midatech Pharma PLC (LON:MTPH) last released its quarterly earnings results on Thursday, September 28th. The company reported GBX (19) (($0.25)) earnings per share for the quarter. Midatech Pharma PLC had a negative net margin of 262.24% and a negative return on equity of 43.66%. The business had revenue of GBX 302 million for the quarter.

TRADEMARK VIOLATION WARNING: “N+1 Singer Trims Midatech Pharma PLC (MTPH) Target Price to GBX 96” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/13/n1-singer-trims-midatech-pharma-plc-mtph-target-price-to-gbx-96.html.

About Midatech Pharma PLC

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.